Aequus Pharmaceuticals Inc. (AQSZF)
OTCMKTS
· Delayed Price · Currency is USD
0.0040
0.00 (0.00%)
At close: May 2, 2025
Aequus Pharmaceuticals Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 0.58 | 0.25 | 1.38 | 2.71 | 2.59 | Upgrade
|
| Revenue Growth (YoY) | 129.21% | -81.53% | -49.17% | 4.71% | 58.81% | Upgrade
|
| Cost of Revenue | 0.25 | 0.11 | 0.1 | 0.04 | - | Upgrade
|
| Gross Profit | 0.33 | 0.14 | 1.28 | 2.67 | 2.59 | Upgrade
|
| Selling, General & Admin | 2.71 | 2.66 | 3.69 | 3.98 | 3.32 | Upgrade
|
| Research & Development | - | 0.3 | 0.17 | 0.3 | 0.05 | Upgrade
|
| Operating Expenses | 2.71 | 2.96 | 3.86 | 4.28 | 3.37 | Upgrade
|
| Operating Income | -2.38 | -2.82 | -2.58 | -1.61 | -0.78 | Upgrade
|
| Interest Expense | - | -0.15 | -0.13 | -0.21 | -0.29 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0.02 | 0.01 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0 | 0.04 | -0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.2 | - | -0.57 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -2.18 | -2.96 | -3.21 | -1.81 | -1.06 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.02 | Upgrade
|
| Pretax Income | -2.18 | -2.96 | -3.21 | -1.81 | -1.05 | Upgrade
|
| Net Income | -2.18 | -2.96 | -3.21 | -1.81 | -1.05 | Upgrade
|
| Net Income to Common | -2.18 | -2.96 | -3.21 | -1.81 | -1.05 | Upgrade
|
| Shares Outstanding (Basic) | 133 | 133 | 133 | 129 | 93 | Upgrade
|
| Shares Outstanding (Diluted) | 133 | 133 | 133 | 129 | 93 | Upgrade
|
| Shares Change (YoY) | - | - | 2.94% | 38.28% | 15.86% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | Upgrade
|
| Free Cash Flow | -1.66 | -2.29 | -1.95 | -1.18 | -0.82 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | 56.88% | 56.36% | 92.49% | 98.42% | 100.00% | Upgrade
|
| Operating Margin | -407.47% | -1106.45% | -187.17% | -59.22% | -30.08% | Upgrade
|
| Profit Margin | -372.74% | -1163.11% | -232.65% | -66.66% | -40.32% | Upgrade
|
| Free Cash Flow Margin | -283.44% | -899.97% | -141.51% | -43.33% | -31.52% | Upgrade
|
| EBITDA | -2.37 | -2.81 | -2.58 | -1.6 | -0.69 | Upgrade
|
| EBITDA Margin | - | - | -186.67% | -58.91% | -26.56% | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.09 | Upgrade
|
| EBIT | -2.38 | -2.82 | -2.58 | -1.61 | -0.78 | Upgrade
|
| EBIT Margin | - | - | -187.17% | -59.22% | -30.08% | Upgrade
|
| Revenue as Reported | - | 0.25 | 1.38 | 2.71 | 2.59 | Upgrade
|
| Advertising Expenses | - | 0.23 | 0.24 | 0.22 | 0.1 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.